AbbVie’s Solid Tumor Strategy Gets a Win With Accelerated FDA Approval in Lung Cancer

AbbVie’s Solid Tumor Strategy Gets a Win With Accelerated FDA Approval in Lung Cancer

Emrelis, an antibody drug conjugate developed by AbbVie, is now FDA approved for patients whose non-small cell lung cancer overexpresses the protein c-Met. The pharma company said this ADC is its first internally developed solid tumor medicine as well as its first solid tumor FDA approval in lung cancer. The post AbbVie’s Solid Tumor Strategy Gets a Win With Accelerated FDA Approval in Lung Cancer appeared first on MedCity News.

AbbVie bags first approval for cancer ADC Emrelis

AbbVie has claimed its first global regulatory approval, from the FDA, for its C-met-targeting lung cancer ADC Emrelis

US FDA approves AbbVie’s drug for a type of lung cancer

(Reuters) -The U.S. Food and Drug Administration has approved AbbVie’s drug to treat adults with a type of lung cancer who have received previous treatment, the drugmaker said on Wednesday. The treatment, branded as Emrelis, belongs to a class of drugs known as antibody-drug conjugates (ADC) which are targeted cancer therapies. Emrelis was approved for previously treated patients with non-squamous non-small cell lung cancer whose disease has spr…

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

The FDA approved a new antibody-drug conjugate from AbbVie on Wednesday to treat patients with certain kinds of lung cancer. Regulators granted accelerated approval to telisotuzumab vedotin in second-line non-small cell lung cancer for patients ...

FDA Approves Emrelis in Previously Treated, Advanced NSCLC

The U.S. FDA has approved treatment with Emrelis for adult patients with previously treated, advanced NSCLC with high c-Met protein overexpression.

FDA Grants Accelerated Approval to Telisotuzumab Vedotin In Pretreated Advanced NSCLC With c-MET Overexpression

The FDA approved telisotuzumab vedotin for pretreated advanced NSCLC harboring high c-MET protein overexpression.